Health Network Laboratories (HNL) Enters Into License Agreement With Hunter Laboratories to Provide HunterHeart Cardiovascular Disease Management Program.

ALLENTOWN, Pa. and CAMPBELL, Calif., May 25 /PRNewswire/ -- HunterHeart offers physicians and patients sophisticated risk characterization and personalized therapy guidelines for cardiovascular disease.  HNL will be performing a battery of advanced tests, offering an accompanying nutrition program, and wellness coaching.  Gerry Weiss, MD, Hunter's Medical Director stated:  "With appropriate risk characterization and treatment, cardiovascular disease can be prevented for many patients and MI and stroke events can be significantly reduced."

"HNL's reputation for quality, service and innovation is exceptional.  Hunter is delighted to be working with HNL to reduce cardiovascular disease in PA and NJ," stated Chris Riedel, Hunter's CEO.  HNL's President and CEO, David G. Beckwith Ph.D., stated that, "The HunterHeart program will assist our physicians in delivering comprehensive cardiovascular health advice to their patients, and establishes HNL as a center of excellence for preventive cardiology."

About Health Network Laboratories

Based in Allentown, Pennsylvania, Health Network Laboratories (HNL) is a multi-regional medical laboratory with technologically advanced facilities in Pennsylvania and New Jersey.  HNL serves the need of the public and health care communities performing almost 6 million clinical and pathology tests each year.  HNL is consistently rated highly by physicians and clients in all areas of laboratory performance and customer satisfaction.

HNL offers a full complement of clinical laboratory and anatomic pathology services, including highly specialized esoteric testing to hospitals, physicians, long-term and assisted living facilities, businesses and government agencies.  For more information, visit http://www.healthnetworklabs.com/

About Hunter Labs, Inc.

Hunter Laboratories is the largest locally owned and operated clinical reference laboratory in northern California.  HunterHeart is one of Hunter's proprietary disease detection and management programs that are being rolled-out across the U.S.  Hunter's Incelldx mRNA test for cervical cancer detection is also being introduced across the U.S.  This test is the only accurate HPV method for women under 30, and has better specificity for predicting CIN2/CIN3 on biopsy.  For more information, visit http://www.hunterlabs.com/.

SOURCE Hunter Laboratories